GlassScriptPhysician profile
Alejandro C Ojascastro
NPI 1154437994
$992.66
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $110 · 2021: $39.71 · 2022: $220.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.02 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $163.95 | 2019 | |
| Glaxosmithkline, LLC. | $121.56 | 2019 | |
| Novo Nordisk INC | $57.01 | 2019 | |
| Avion Pharmaceuticals | $54.82 | 2019-2021 | |
| Exeltis, USA INC. | $40.45 | 2019-2020 | |
| Lilly USA, LLC | $36.66 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.56 | 2019 | |
| Allergan, INC. | $35.95 | 2019 | |
| Lupin INC. | $25.64 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $16.90 | 2019 | |
| Tris Pharma INC | $12.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Ojascastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.